TWST Twist Bioscience Corp stock chart & analysis

Conviction 36HealthcareScan · Fri, Nov 6, 2026

Twist Bioscience Corp (TWST) closed at $120.79 (+0.15%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 39, RS Rating 99, -45.0% from its 52-week high, +281.0% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

TWST$120.79+0.15%

ResistanceSupportVol 14Insider sell

Loading chart…

Twist Bioscience CorpBiological Products, (No Diagnostic Substances)www.twistbioscience.com ↗

Price120.79

Change+0.15%

Gap+1.75%

Rel volume1.09×

Avg volume2.38M

Avg $ vol343.86M

SMA 20144.69

SMA 50151.35

SMA 20091.22

Price vs 50-20.16%

Price vs 200+32.48%

MA stackmixed

50/200 cross—

Supertrenddown · 172.68

RSI (14)39

MACD hist-3.32

MACD crossbear · 4d

Stoch %K / %D7 / 13

ADX (14)18

+DI / −DI18 / 29

RSI divergence—

MACD divergence—

ATR %13.07%

ADR %10.10%

52w high219.71

52w low23.30

From 52w high-45.00%

Above 52w low+418.63%

New 52w highNo

SqueezeOff

Bollinger width37.97%

%B0.07

Donchian pos6.83%

Donchian high178.53

Donchian low116.61

AVWAP (52w high)151.73

vs AVWAP high-20.36%

AVWAP (52w low)92.20

vs AVWAP low+31.06%

OBV trendFlat

Chaikin MF (20)-0.00

Today vs 20d1.09×

Avg vol (14d)2.38M

Avg vol (20d)2.38M

Avg $ vol (20d)343.86M

Market cap7.58B

RS Rating99 / 99

RS 3m (vs SPY)+1.63%

RS 6m (vs SPY)+112.86%

RS line new highNo

Trend template6/8

Technical rank66.0

1 week-20.91%

1 month-20.53%

3 months-3.24%

6 months+112.56%

1 year+283.38%

YTD+280.96%

P/E-97.56

P/B17.00

P/S20.12

P/FCF-100.19

EPS-1.30

Div yield—

ROE-17.42%

ROA-11.55%

Debt/Eq0.00

Current2.67

EV/EBITDA-66.97

Gross margin50.72%

Net margin-20.63%

Rev growth20.32%

EPS growth62.79%

Price target168.88

Target upside39.76%

Analyst ratingBuy

Institutional123.76%

Ent. value7.46B

Revenue118.38M

Net income-35.05M

Gross profit62.45M

Free cash flow-75.63M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out62.27M

Employees979

ListedWed, Oct 31, 2018

Free float52.76M

Float %86.1%

Short interest—

Days to cover—

Short volume58.7%

Squeeze score—

Next earningsNov 12 · pre-mkt (6d)

EPS forecast−$0.44 · 1 est

Last EPS vs est−$0.56 vs −$0.50

Last surprise-12.0% miss

Setup gradeD

Conviction36 / 100

Pattern quality—

Tech rank66.0 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance199.12

Support129.48

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

TWST technical analysis

Trend

TWST's moving averages are mixed — no clean uptrend or downtrend. It closed 20.2% below the 50-day ($151.35) and 32.5% above the 200-day ($91.22). ADX(14) at 18 points to a weak trend — more range than direction. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 39, in the bearish half of its range. MACD crossed below its signal line 4 sessions ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.

Volume and volatility

Volume on the latest session ran 1.1× its 20-day average. It trades about $343.9M a day on average. ATR(14) is $15.80, 13.1% of price — its typical daily range.

Key levels

The chart pattern's support is $129.48 and its resistance $199.12. The 52-week range is $23.30 to $219.71; price is 45.0% below the high and 418.6% above the low. The VWAP anchored at the 52-week high is $151.73, above price.

Performance

TWST returned -20.9% (1 week), -20.5% (1 month), -3.2% (3 months), +112.6% (6 months), +283.4% (1 year), +281.0% (year to date).

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Biological Products, (No Diagnostic Substances) · Listed 2018 · 979 employees

Insider activity

SEC Form 4 transactions in TWST · open-market 10 sells

Insider	Side	Shares	Value	Traded	Filed
Finn Patrick John President and COO · Common Stock · 2026-11-03	Sell	2.56K	$347K	2026-11-03	2026-11-05
Green Paula SVP of Human Resources · Common Stock · 2026-11-03	Sell	1.01K	$136K	2026-11-03	2026-11-05
Leproust Emily M. Chief Executive Officer · Common Stock · 2026-11-03	Sell	4.57K	$619K	2026-11-03	2026-11-05
WERNER ROBERT F. Chief Accounting Officer · Common Stock · 2026-11-03	Sell	148	$20K	2026-11-03	2026-11-05
Cho Dennis See Remarks · Common Stock · 2026-11-03	Sell	949	$128K	2026-11-03	2026-11-05
Finn Patrick John President and COO · Common Stock · 2026-10-23	Sell	2.25K	$302K	2026-10-23	2026-10-27
Leproust Emily M. Chief Executive Officer · Common Stock · 2026-10-05	Sell	1.84K	$369K	2026-10-05	2026-10-07
Leproust Emily M. Chief Executive Officer · Common Stock · 2026-10-05	Sell	481	$97K	2026-10-05	2026-10-07
Leproust Emily M. Chief Executive Officer · Common Stock · 2026-10-05	Sell	1.02K	$206K	2026-10-05	2026-10-07
Leproust Emily M. Chief Executive Officer · Common Stock · 2026-10-05	Sell	432	$88K	2026-10-05	2026-10-07

SEC filings

EDGAR filings in TWST · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.